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The yellow fever vaccine 17D (17D) is safe, and after a single immunizing dose, elicits long-
lasting, perhaps lifelong protective immunity. One of the major challenges facing delivery of 
human vaccines in underdeveloped countries is the need for multiple injections to achieve 
full efficacy. To examine 17D as a vector for microbial T cell epitopes, we inserted the 
H-2K
 
d
 
–restricted CTL epitope of the circumsporozoite protein (CS) of 
 
Plasmodium yoelii
 
 
between 17D nonstructural proteins NS2B and NS3. The recombinant virus, 17D-Py, was 
replication competent and stable in vitro and in vivo. A single subcutaneous injection of 
10
 
5
 
 PFU diminished the parasite burden in the liver by 
 
 
 
70%. The high level of protection 
lasted between 4 and 8 wk after immunization, but a significant effect was documented 
even 24 wk afterwards. Thus, the immunogenicity of a foreign T cell epitope inserted into 
17D mimics some of the remarkable properties of the human vaccine. Priming with 17D-Py 
followed by boosting with irradiated sporozoites conferred sterile immunity to 90% of the 
mice. This finding indicates that the immune response of vaccine-primed individuals living in 
endemic areas could be sustained and magnified by the bite of infected mosquitoes.
 
Many human vaccines that are currently in use
require multiple injections to be fully effective
over the long term. This requirement is a severe
hurdle for their utilization, particularly in
underdeveloped countries where they are
much needed. One notable exception is the yel-
low fever vaccine using the attenuated YF17D
strain (17D). Developed in the 1930s, this live,
highly attenuated viral vaccine has been given
to hundreds of millions of individuals with
minimal risk of severe side effects. Administra-
tion of a single dose of this genetically stable
vaccine confers excellent protection that per-
sists for 30 or more years, perhaps lifelong (1).
The mechanisms of protection are not well
understood, but they involve the production
of neutralizing antibodies and probably the
production of T cell–mediated immune mech-
anisms (2, 3).
In recent years, the remarkable properties
of 17D vaccine have been exploited to create
candidate vaccines against other flavivirus-
mediated diseases by exchanging the premem-
brane and envelope genes of 17D with those
of Japanese encephalitis, dengue types 1–4, and
West Nile viruses. These chimeric viruses repli-
cate to high titers in cell culture, elicit protec-
tive immunity in rodents and monkeys (4, 5),
and retain or surpass the monkey neurovirulence
safety standards set for 17D (6). Phase I human
trials for some of these hybrid vaccines have
been initiated.
However, the 17D vaccine has not been
used as a vector to deliver epitopes from unre-
lated microbial pathogens. The only exception
has been the successful insertion of the immuno-
dominant protective B cell epitope of the cir-
cumsporozoite (CS) protein of the human
malaria parasite, 
 
Plasmodium falciparum
 
, into the
envelope protein of 17D. The genomic stability
of that recombinant virus, named 17D/8, was
confirmed by serial in vitro passages. Immuni-
zation of mice with 17D/8 led to long lasting
production of antibodies to 
 
P. falciparum
 
 sporo-
zoites. In addition, immune serum neutralized
the infectivity of wild-type YF virus (7).
Here, we studied the immunogenicity of a
recombinant 17D virus expressing the protec-
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tive H-2K
 
d
 
–restricted CTL epitope of the CS protein of 
 
P.
yoelii
 
, a rodent malaria parasite (8). In this experimental
model, a rapid and quantitative assessment of protective im-
munity is feasible upon sporozoite challenge of immunized
mice. Moreover, the efficacy of different viral vaccine con-
structs can be compared. This experimental model has pro-
vided the basis for the development of various human ma-
laria vaccine candidates that underwent clinical trials (9, 10),
as well as some currently undergoing human trials.
 
RESULTS
Insertion of the malaria CD8
 
 
 
 T cell epitope 
in the genome of 17D
 
We inserted a 10-amino acid-long H-2K
 
d
 
 CTL epitope of the
CS protein of 
 
P. yoelii
 
 (SYVPSAEQIL) in 17D polyprotein in
frame between the NS2B and NS3 nonstructural proteins
(Fig. 1 A). The foreign epitope sequence was flanked by viral
protease recognition sites in order to release the epitope in the
cytoplasm of the host cell leaving unaltered functional viral
replicase proteins. This strategy and the insertion site were
chosen based on a previous observation showing that an oval-
bumin epitope, inserted in the same site, yielded viable re-
combinant virus that elicited the production of ova-specific
CTL and protection in a rodent tumor model (11).
The recombinant construct was designated 17D-Py and
the parental 17D2B/3 (referred to as 17D in this paper). The
infectivity of RNAs transcribed from linearized plasmid tem-
plates was tested by electroporation of human SW-13 cells.
Both the 17D-Py and the parental 17D RNAs had similar
specific infectivities of 
 
 
 
5 
 
 
 
 10
 
5
 
 PFU/
 
 
 
g RNA (Fig. 1 B).
17D-Py plaques were slightly larger than those of the parental
virus. We compared the growth kinetics of 17D-Py and 17D
after infecting SW-13 cells at either low (0.1 PFU/cell) or
high (5 PFU/cell) multiplicities of infection (MOIs). Interest-
ingly the 17D-Py recombinant exhibited faster growth kinet-
ics at both MOIs than the 17D parent, although similar
plateau titers were obtained for both viruses. To assess the sta-
bility of the inserted sequence in cell culture, transfection su-
pernatants were used to infect naive SW-13 cells at low MOI
(0.1 PFU/cell). The resulting virus-containing supernatant
was harvested and analyzed for the presence of the CTL
epitope by RT-PCR, restriction digestion, and sequence
analysis. As shown in Fig. 1 D, the RT-PCR products were
of the expected sizes and the fragment from 17D-Py was di-
gested to completion with SspI, which is present in the in-
serted 
 
P. yoelii
 
 sequence. Sequence analysis of the RT-PCR
products revealed the expected sequences.
 
In vivo stability of 17D-Py
 
Young mice are highly permissive for flavivirus infection and
succumb to virus-induced paralysis. To examine the stability
of the recombinant virus in vivo, we injected 10
 
5
 
 PFU of the
recombinant 17D-Py or parental 17D viruses i.p. into suck-
ling mice. All of the mice eventually became paralyzed by
Figure 1. Construction and viability of 17D-Py virus. (A) Schematic 
representation of P. yoelii CTL SYVPSAEQIL epitope insertion into the 
YF17D genome. The NS2B/NS3 protease recognition sequence was dupli-
cated flanking the CTL epitope. (B) Infectious center assay from SW-13 
cells transfected with 17D or 17D-Py RNAs. Plaques were fixed in 7.5% 
formaldehyde and stained by crystal violet. (C) One-step growth curve of 
17D or 17D-Py in SW-13 cells infected at low (0.1 PFU/cell) or high (5 PFU/
cell) multiplicity. Virus titers were measured by plaque assay on SW-13 
cells as described in Materials and methods. The graphs represent the 
mean of three independent infections. (D) RT-PCR products of the 2B/3 
region amplified from viral RNA recovered after infection of naive SW-13 
cells with 17D or 17D-Py1 (in vitro) or from brain homogenate of suckling 
mice injected i.p. with each virus (in vivo). The fragments were digested 
with SspI and run on a 5% acrylamide gel. The P. yoelii CTL insert contains 
an SspI site not present in 17D. 
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10–14 d after infection. The infectious virus could be recov-
ered from brain homogenates of the moribund animals, with
high viral titers ranging from 5 
 
 
 
 10
 
5
 
 to 5 
 
 
 
 10
 
6
 
 PFU per
brain. Viral RNA was recovered from clarified brain homog-
enates and assayed for the presence of the insert as described
above. As found in cell culture, the expected RT-PCR
products were obtained, and the 17D-Py product was di-
gested with SspI (Fig. 1 D). In addition, sequencing of the
RT-PCR products revealed the expected input sequences.
These analyses indicate that the 
 
P. yoelii
 
 insert is still present
in the recombinant virus after multiple cycles of replication
in vivo.
 
A single dose of 17D-Py elicits long-lasting immunity 
against malaria
 
Groups of 6–10-wk-old BALB/c (H-2K
 
d
 
) mice were im-
munized with a single viral dose by the s.c. route, using 20-
fold dilutions of viral doses, from 10
 
2
 
 PFU to 10
 
6
 
 PFU of
17D-Py per mouse. 2 wk later, the mice were challenged in-
travenously with 20,000 sporozoites. After 40–42 h, close to
the near completion of the exoerythrocytic stage (EEF) cy-
cle, the animals were killed, and the efficacy of immuniza-
tion was evaluated by enumerating IFN
 
 
 
-secreting CS-spe-
cific CD8
 
 
 
 T cells in the spleen, and by measuring the
parasite burden in the liver, as compared with controls im-
munized with parental 17D (10
 
5
 
 PFU). As shown in Fig. 2,
and in several subsequent experiments, immunization with
10
 
5
 
 PFU elicited 
 
 
 
67% inhibition of EEF development.
Notably, a considerable degree of inhibition (52%) was ob-
tained with viral doses as low as 5 
 
 
 
 10
 
3
 
 PFU (Fig. 2).
To test the longevity of the protective immune response in-
duced by vaccination with 17D-Py, groups of mice were in-
jected s.c. at weekly intervals for 24 wk, with a single dose of
10
 
5
 
 PFU of the recombinant virus. 1 wk after the last mice had
been immunized, all mice were challenged as described earlier
in the paper. Inhibition of liver stage parasite burden peaked
between 4 and 8 wk after immunization, but was still apprecia-
ble for at least 24 wk (Fig. 3 A). The number of CS-specific
CD8
 
 
 
 T cells of these mice followed a similar course (Fig. 3 B).
 
Heterologous prime/boost regimens can achieve 
sterilizing immunity
 
We first tried a series of homologous boost regimens with
17D-Py. No significant differences in parasite burden were
seen in mice given either one dose or five consecutive daily
injections of 10
 
4
 
 or 10
 
5
 
 PFU of 17D-Py (Fig. 4 A, groups A
and B, respectively). In mice boosted with 10
 
5
 
 PFU 3 wk
after priming, the EEF burden was significantly reduced,
which correlated with an increase in the number of IFN
 
 
 
-
secreting CS-specific CD8
 
 
 
 T cells (Fig. 4, A and B). The
highest degree of protection (close to 90% reduction in para-
site burden) was obtained when the smallest viral dose (10
 
3
 
PFU) was used for priming (Fig. 4, group E).
It is well documented that the prime/heterologous boost
strategy elicits very strong immune responses when using vi-
ral vaccine vectors. In previous experiments, the vaccinia vi-
rus or the modified vaccinia Ankara virus (MVA) expressing
the CS of 
 
P. yoelii
 
 greatly enhanced primary responses to in-
fluenza or Sindbis virus expressing the same CD8
 
 
 
 T cell
malaria epitope (12–15). We found that priming mice with
different doses (10
 
2
 
 –10
 
5
 
 PFU) of 17D-Py, and boosting 2
wk later with a single intravenous dose (10
 
7 
 
PFU) of MVA-
PyCS elicited large numbers of CS-specific IFN
 
 
 
-secreting
CD8
 
 
 
 T cells, antibodies to sporozoites (IFA titers, 1,600-
3,200), and very effective protection (Fig. 5, A and B). Close
to a 100% decrease in parasite burden in the liver was seen
when the challenge was given 2–16 wk after priming with
10
 
5
 
 PFU. This protection lasted for at least 16 wk after
Figure 2. Effect of viral dose on vaccine efficacy. Inhibition of devel-
opment of parasite liver stages in groups of five mice immunized with 20-
fold increasing concentrations of 17D-Py. Control mice received the 17D 
virus (5   105 PFU). Results are expressed as the mean   SE of five mice 
per group.
Figure 3. Persistence of protection and CS-specific CD8  T cell–
mediated responses in mice immunized with 17D-Py. (A) Percentage of 
inhibition of development of parasite liver stages in groups of five mice 
that were challenged with P. yoelii sporozoites, at different times after 
immunization with 17D-Py. (B) Number of IFN -secreting spleen cells 
after in vitro stimulation with the P. yoelii CS CD8  T cell epitope. In this 
and subsequent experiments, splenocytes were harvested 40 h after challenge. 
Results are expressed as the average   SE of five mice per group. 
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boosting, which is when the experiment was terminated
(Fig. 6, A and B).
To further document the high level of protection, an-
other group of animals was primed with 10
 
5
 
 PFU of 17D-Py
and boosted with 10
 
7
 
 PFU of MVA-PyCS. These animals
were challenged at various times after the prime/boost im-
munization with 75 live 
 
P. yoelii
 
 sporozoites and the periph-
eral blood was examined for 2 wk for the presence of blood
stages of the parasite. As shown in Table I, sterile immunity
was observed in 80% of the animals. Even when the chal-
lenge was performed 16 wk after the boost, 40% of the mice
still failed to develop detectable parasitemia.
In malaria-endemic areas, vaccinated individuals are likely
to be frequently bitten by infected mosquitoes. To deter-
mine the effect of a sporozoite boost in our model, mice
primed with 10
 
5
 
 PFU of 17D-Py were injected i.v. with 10
 
4
 
irradiated 
 
P. yoelii
 
 sporozoites (Fig. 7) or were subjected to
the bites of 20–40 irradiated, infected mosquitoes (not de-
picted). 2 wk after the boost, these mice were challenged
with 2 
 
 
 
 10
 
4
 
 live sporozoites. As shown in Fig. 7 A, boost-
ing with sporozoites substantially increased protection, in-
hibiting EEF development by 99%.
In another series of experiments, we sought to determine
whether the prime/sporozoite boost regimen led to sterile
immunity. The animals were challenged i.v. with 75 sporo-
zoites, and we examined them daily for parasitemia for 2 wk.
Sterile immunity was achieved in 9 out of 10 sporozoite-
boosted animals. This protection lasted at least 16 wk after
the sporozoite booster (Table II). In contrast, all control
mice primed with either 17D-Py or vaccinated once with ir-
radiated sporozoites became parasitemic.
 
Mechanism of protection
 
As aforementioned, the prime/boosting regimen led to the
production of antibodies to CS as well as IFN
 
 
 
-secreting
CD8
 
 
 
 T cells. To determine the protective mechanisms,
groups of mice were injected with antibodies to CD4
 
 
 
 or
Figure 4. Effect of a homologous boost with 17D-Py. Mice in groups 
A and B were immunized with 105 or 104 PFU of 17D-Py1, respectively, on 
five consecutive days, and challenged 2 wk later with 2   104 sporozoites. 
Mice in groups C, D, and E were primed with decreasing doses of 17D-Py 
(105, 104, or 103 PFU respectively), and boosted with 105 PFU 2 wk later. All 
animals in these groups were challenged with 2   104 sporozoites. In this 
and subsequent figures, the number of background spots in nonvaccinated 
control samples (naive) ranged between 0 and 4 (*). Results are expressed 
as the mean   SE of five mice per group. (A) Inhibition of development of 
parasite liver stages. (B) Number of IFN -secreting spleen cells after in 
vitro stimulation with the P. yoelii CS CD8  T cell epitope.
Figure 5. Effect of a heterologous boost with MVA-PyCS. Groups of 
five mice were primed with different doses of 17D-Py and boosted i.v. 
2 wk later with 107 PFU of MVA-PyCS. All mice were challenged 2 wk later 
with 2   104 sporozoites. Results are expressed as the mean   SE of five 
mice per group. (A) Inhibition of development of parasite liver stages. 
(B) Number of IFN -secreting spleen cells after in vitro stimulation with 
the P. yoelii CS CD8  T cell epitope.
 
Table I.
 
Sterile immunity induced by 17D-Py 
prime/MVA-PyCS boost
 
Weeks
after boost
Protected/
challenged
Sterile
immunity
 
%
 
2 8/10 80
4 8/10 80
8 6/10 60
16 4/10 40
Control
 
a
 
0/10 0
 
Groups of mice were immunized as described in the legend of Fig. 5. After challenge 
with 75 sporozoites, the peripheral blood of the mice was examined daily for 2 wk for 
the presence of blood stages of the parasite.
 
a
 
The control group consisted of naive mice challenged and analyzed in the same way. 
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CD8
 
 
 
 to deplete these T cell compartments just before chal-
lenge. After ablation of CD8
 
 
 
 T cells, protection was abol-
ished, but depletion of CD4
 
  T cells had no effect as deter-
mined by ELISPOT and tetramer assays (Fig. 8).
DISCUSSION
Here, we use for the first time the highly attenuated YF17D
as a vaccine vector to deliver a microbial T cell epitope. The
YF17D virus, like other flaviviruses, is encoded by a single
positive stranded RNA molecule. Translation of the viral
message produces a polyprotein precursor that is cleaved by
viral and cellular proteases (16). We inserted a CTL epitope
of the CS protein of P. yoelii between the two nonstructural
17D viral proteins, NS2B and NS3, and generated the re-
combinant virus 17D-Py. The most important observation of
this paper is that the injection of a single dose of 105 PFU of
17D-Py elicited a long lasting, high level of protection against
challenge with highly infective sporozoites of P.yoelii. A sig-
nificant degree of protection was seen with doses as small as
103 PFU. Other viral vectors bearing the same CTL epitope
of CS has been used in rodent malaria models. However, like
in other human vaccines currently in use, the T cell response
after priming alone was of short duration. More importantly,
protection against sporozoite challenge usually required one
or more booster injections. Therefore, it appears that the
immunogenicity in mice of T cell epitope inserted in the
YF17D vaccine is distinctive and mimics the immunogenic-
ity of the 17D vaccine in humans; i.e., it is long lasting and
effective after priming.
Our findings provide strong support for using 17D as a
general vaccine vector, even though there is scant informa-
tion on the molecular mechanisms leading to the long-term
memory that it evokes in humans. It is generally believed
that protection in vaccinated humans is mediated in large
part by neutralizing antibodies against the envelope protein
E and complement-fixing antibodies to NS1, but the func-
tional epitopes have not been identified. Human CTL re-
sponses to the vaccine have been documented (2), but there
is no evidence that these vaccine-induced T cell responses
have a role in protection. However, in mice, T cell epitopes
in the envelope protein E and NS3 proteins are targets of an-
Figure 6. Persistence of protection after a heterologous MVA-PyCS 
boost. Groups of five mice were primed with 105 17D-Py and boosted 2 wk 
later i.v. with 107 PFU of MVA-PyCS. The groups of mice were challenged 
with sporozoites between 2 and 16 wk after the boost. Results are expressed 
as the mean   SE of five mice per group. (A) Inhibition of development of 
parasite liver stages. (B) Number of IFN -secreting spleen cells after in 
vitro stimulation with the P. yoelii CS CD8  T cell epitope.
Figure 7. Effect of a sporozoite boost. Groups of mice were primed 
with 105 17D-Py and, 2 wk later, were injected i.v. with 104 irradiated 
sporozoites. 2 wk later, the mice were challenged with 2   104 nonirradi-
ated sporozoites. Controls were immunized with either 17D-Py or just 
with irradiated sporozoites, and challenged at the same time. Results are 
expressed as the mean   SE of five mice per group. (A) Inhibition of devel-
opment of parasite liver stages. (B) Number of IFN -secreting spleen cells 
after in vitro stimulation with the P. yoelii CS CD8  T cell epitope.
Table II. Sterile immunity induced by 17D-Py prime/iSP boost
Group
Weeks after last
immunization
Protected/
challenged
Sterile
immunity
%
Naive N/A 0/5 0
ISP 2 0/5 0
17D-Py 2 0/5 0
17D-Py/iSP 2 9/10 90
17D-Py/iSP 16 6/10 60
One group of mice that had been primed with 17D-Py was boosted 2 wk later with 
104 irradiated sporozoites. 2 wk later, the last immunization all mice were infected 
with 75 sporozoites i.v. For controls, groups of mice were either not immunized 
(naive), primed with 104 irradiated sporozoites (iSP), or with 5   105 PFU 17D-Py 
(17D-Py). The peripheral blood of the mice was examined daily for 2 wk for the 
presence of blood stages of the parasite. The complete absence of detectable blood 
infection was taken as evidence for sterile immunity. MALARIA VACCINATION USING RECOMBINANT YELLOW FEVER VIRUS | Tao et al. 206
tiviral responses (3). Regardless of the protective mechanism,
vaccination with 17D seems to be sufficient for triggering
the programs of expansion and differentiation of long-lived
memory cells.
The mechanism of induction of primary CD8  T cell re-
sponses to the malaria epitope in 17D-Py is not known but
currently under investigation. The small CTL epitope is in-
serted between NS2B and NS3 and should be released in the
cytoplasm of the infected cell. In vivo, the 17D vaccine is
administrated subcutaneously and may infect professional
APCs (pAPCs), such as dendritic cells, and/or parenchymal
cells. However, CTL responses can only be generated by
pAPCs. If the virus multiplies in a parenchymal cell, its rem-
nants and viral antigens need to enter the pAPCs to initiate a
primary response via cross-presentation. However, several
independent lines of evidence show that short-lived peptides
such as the malaria epitope cannot be cross-presented (17).
The implication is that only the 17D-infected pAPCs partic-
ipate in the initial sensitization of T cells. It will be of inter-
est to determine the nature of the cells that are initially in-
fected by 17D. A preference for pAPCs would provide an
explanation for its unusually strong immunogenicity. In fact,
dengue virus, which belongs to the same genus as YF, pref-
erentially targets immature dendritic cells (18).
Another important finding is that the resulting recombi-
nant virus 17D-Py is not only replication competent, but
also stable in vitro and in vivo, thus minimizing the concern
that the heterologous insert would be eliminated or modi-
fied during viral replication. However, if 17D is to be used
as a general vaccine vector for multiple CTL epitopes, it
will be necessary to understand the size and sequence con-
straints for inserting several microbial sequences in the same
or in other positions in the 17D genome. We have recently
shown that three tandem repeats of the same P. yoelii epitope
can be inserted between NS2B and NS3 (unpublished data).
This 17D recombinant replicates with kinetics similar to the
17D parent and is also stable in vitro and in vivo. Therefore,
the potential already exists for vaccination with mixtures of a
few recombinant viruses, each containing strings of three
different protective T cell epitopes, to elicit immune re-
sponses in a large proportion of humans.
The present results are of particular relevance to the de-
velopment of preerythrocytic human malaria vaccines. Their
targets are the sporozoites that enter the host during the
mosquito bite, and the liver stages (EEFs). P. falciparum vac-
cines that target CS, the main surface protein of sporozoites,
are undergoing human trials. One of them named RTS,S
protects 50% or more of naive volunteers (19), or individu-
als living in an endemic area in Africa. However, protec-
tion lasts only for a couple of months (20). The mechanism
of protection involves neutralizing antibodies and effector
CD4  T cells (21). CS vaccines that elicit additional effector
CD8  T cells would be highly desirable. In the rodent mod-
els of malaria, there is compelling evidence that CTL can de-
stroy the early EEFs by releasing IFN  (22). In addition,
production of specific antibodies, such as after MVA-PyCS
injection, can only reduce the number of EEF in the liver.
Furthermore, CS is produced in large amounts during EEF
development and is processed and presented on the surface
of the infected liver cells (23, 24). As shown here CS is an
excellent target for CTL. Indeed, priming mice with 17D-
Py that contains a single CS CTL epitope leads to the elimi-
nation of 60–70% of liver stages. This is particularly note-
Figure 8. CD8  T cells mediate protection. Groups of mice were immu-
nized by the prime/boost regimen as described in the legend of Fig. 5. 
3 d before the challenge with 2   104 sporozoites and daily thereafter, the 
mice received i.p. injections of 0.1 mg of antibodies specific for CD4  or 
CD8  T cells. Results are expressed as the mean   SE of five mice per 
group. (A) Inhibition of development of parasite liver stages before and 
after depletion of T cells. (B) Number of IFN -secreting spleen cells after in 
vitro stimulation with the P. yoelii CS CD8  T cell epitope. (C) Frequency of 
tetramer-stained SYVPSAEQI-specific T cells.JEM VOL. 201, January 17, 2005 207
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worthy because priming of mice using other recombinant
viral vectors such as influenza or vaccinia expressing the
same malaria CD8  CTL epitope do not lead to protective
responses without boosting (12, 15). In the case of Sindbis
vectors, protection is optimal 12 d after priming (14), but
decays quickly afterwards (Tsuji, M., personal communica-
tion). Another observation important for malaria vaccine de-
velopment is the finding that the protection elicited by 17D-
Py can be boosted with sporozoites and that the boosting
leads to sterile immunity. It is therefore plausible that in en-
demic areas the immune response of vaccinated individuals
will be magnified by the bite of infected mosquitoes.
This is particularly encouraging considering that the vac-
cines actually undergoing clinical trials for malaria in en-
demic areas are based on a prime/boost strategy involving
two priming immunizations 3 wk apart, a boost 3 wk later,
and finally another boost after 12 mo (25). In contrast,
YF17D is able to induce neutralizing antibodies in 90% of
vaccine recipients 10 d after vaccination, and the percentage
increases to 99% after 4 wk. Moreover, the fact that YF vac-
cination has been included since 1993 in the World Health
Organization (WHO)–sponsored Expanded Program on Im-
munization for children in developing countries (26) could
facilitate the introduction of a recombinant YF/malaria vac-
cine in those countries where it is most needed. Our results
showing that such recombinant viruses can be viable, stable
in vivo, and are able to induce an effective antimalarial im-
munity in the P. yoelii-mouse model are encouraging for fu-
ture attempts targeting P. falciparum. Although such vaccine
candidates will not be readily testable for protection against
malaria short of human clinical trials, their safety, immuno-
genicity, and protective efficacy against virulent YF can be
tested in rhesus macaques.
Yellow fever 17D is a remarkably safe and effective vac-
cine, but adverse effects have been noted. Over 60 yr, an es-
timated 400 million doses have been administered world-
wide with 2 deaths due to encephalitis. From 1996 to 2001,
150 million doses were administered and seven cases of
vaccine-associated viscerotropic disease (including six deaths)
occurred. The cause of this rare, but severe, reaction is un-
known; but, it seems to involve an atypical host response
rather than reversion of the vaccine virus to virulence (27–
29) and the WHO guidelines regarding the vaccine have re-
mained unchanged (30). This would certainly not contrain-
dicate vaccination in malaria-endemic countries.
Finally, one can envision modernizing the 17D vaccine
or 17D recombinant vaccine candidates. Currently, a stan-
dardized seed lot inoculum is amplified in embryonated
chicken eggs and a crude homogenate stored frozen after
lyophilization. This vaccine is difficult to manufacture, ex-
pensive, and requires refrigeration. Recombinant plasmid
DNAs can now be used as a stable repository for the vaccine
with seed stocks and vaccine lots generated by amplification
in cell culture. Beyond this, recent work has shown that fla-
viviruses can be launched directly from transfected plasmid
DNA (31), making it possible to eliminate cell culture prop-
agation completely. Such new approaches offer the advan-
tages of the DNA vaccines, ease of manufacture, and the
possibility of bypassing the cold chain.
MATERIALS AND METHODS
Plasmids and recombinant viruses. For 17D2B/3, we modified the
17D genome (32) to introduce a BssHII and a BstEII cleavage site at the
recognition site of the viral serine protease NS2B-NS3, as described by
McAllister and colleagues (11).
For 17D-Py, we engineered the CTL epitope of Plasmodium yoelii
(SYVPSAEQIL) into the 17D genome by assembly PCR using two specific
oligonucleotides containing the P.yoelii CTL sequence (forward, GGA-
GCGCGCAGAAGTTCTTATGTCCCAAGCGCAGAACAAATATTAG
GTCACCGGAGAA; and reverse, CCGGTGACCTAATATTTGTTCTG-
CGCTTGGGACATAAGAACTTCTGCGCGCTCCCCTGACAT) and
two 17D-specific primers to generate two PCR fragments containing the P.
yoelii CTL and a portion of the NS2B or NS3 gene, respectively. 1  l out
of 50  l of each PCR reaction was mixed together and was used as template
for a PCR with 17D-specific primers lying in NS2B and in NS3. The final
PCR product was digested with BssHII and a BstEII and cloned into
17D2B/3.
MVA-PyCS is an MVA recombinant that expresses the entire CS protein
of P.yoelii (12) and was used for heterologous boosting in some experiments.
Preparation of 17D and 17D-Py virus stocks. The parental 17D and
recombinant 17D-P.yoelii plasmids were purified by banding on CsCl and
linearized by digestion with XhoI. The linearized template was transcribed
by SP6 RNA polymerase in the presence of cap analogue, purified, and
used to electroporate SW-13 cells as described previously (33). The specific
infectivity of the viral RNA was measured by seeding serial dilutions of
transfected cells on monolayers of untransfected SW-13 cells, overlaying
with 0.6% agarose in medium, and counting viral plaques after 96 h. Virus
stocks were harvested at 48 h after electroporation with typical yields of
107–108 PFU/ml, as determined by a plaque assay on SW-13 cells. Single
use aliquots were stored frozen at –80 C until use.
17D growth and stability in cell culture. SW-13 cell monolayers were
infected with parental 17D or recombinant 17D-Py at low (0.1 PFU/cell) or
high (5 PFU/cell) multiplicity. Supernatants were collected at various times
after infection and frozen at  80 C. For plaque titration, serial 10-fold dilu-
tions were used to infect monolayers of SW-13 cells. After 1 h at 37 C, cells
were overlayed with 0.6% agarose in medium and the plaques counted at 96 h
after fixation with formaldehyde and staining with crystal violet (33).
To assess the stability of the inserted sequence, virus in the supernatants
was concentrated by PEG precipitation (34), and the RNA was isolated by
TRIzol extraction according to the manufacturer’s instructions. First-strand
cDNA was synthesized using SuperScript II reverse transcriptase (Invitro-
gen) and random hexamers and amplified by PCR using 17D-specific oli-
gonucleotides flanking the 2B/3 insertion site. Products were sized by
acrylamide gel electrophoresis, cleaved with a restriction enzyme diagnostic
of the P. yoelii epitope sequence (SspI) or sequenced as a population.
Animals and parasites. P. yoelii (17X NL strain) was maintained by al-
ternate cyclic parasite passage in Anopheles stephensi and infected blood trans-
fer to mice. Sporozoites were obtained by dissection of salivary glands of A.
stephensi and collected in medium RPMI 1640 at 4 C.
BALB/c and C57BL/6 mice were obtained from Charles River Labora-
tories. Animals were maintained in the animal facility of the Department
of Medical and Molecular Parasitology. All animal experimental procedures
were reviewed and approved by the Institutional Animal Review committee.
Immunization, challenge, and in vivo stability of recombinant
viruses. Except when stated otherwise in the figure legends, mice were
primed with 5   105 PFU of 17D-Py injected s.c. When given a boost, this
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route, MVA-PyCS (107 PFU), or irradiated sporozites injected i.v. Immu-
nized mice were challenged i.v. with 2   104 sporozoites 2 wk after immu-
nization, except when otherwise noted.
Newborn C57BL/6 mice were injected in the peritoneum with 105
PFU of 17D (seven mice) or 17D-Py (five mice). All mice developed hind
limb paralysis 10–14 d after infection. Virus was recovered from spleen and
brain homogenates, and titers were determined by plaque assay (33). Virus in
clarified homogenates was concentrated by PEG precipitation and RNA iso-
lated by TRIzol extraction. The presence of Py insert was assessed by RT-
PCR amplification, restriction digestion, and sequencing as described above.
Evaluation of immunogenicity and protective immunity. In most ex-
periments, after each vaccination regimen, we evaluated the protective im-
munity (inhibition of the EEF development) and malaria-specific CD8  T
cell responses. The degree of protection against sporozoite challenge elicited
by the vaccination was evaluated by two criteria: the level of inhibition of de-
velopment of liver stages (EEFs), and the absence of parasites in the peripheral
blood of immunized and sporozoite-challenged mice (sterile immunity).
To measure the number of EEFs, livers were harvested 40–42 h after
i.v. challenge with 2   104 sporozoites. This is the time when EEFs are al-
most fully developed, and the newly formed merozoites are nearly ready to
exit the hepatocytes, and enter the blood circulation. Quantification of the
EEFs was done by real-time PCR analysis of parasite specific rRNA. In
most instances, data are presented as the average parasite RNA copies in the
liver  SE in immunized mice, compared with controls vaccinated with
17D virus (35).
Cellular immune responses were evaluated by enumerating IFN -pro-
ducing, epitope-specific CD8  T cells in the spleen (by ELISPOT), as de-
scribed (36). Splenocytes were harvested at 40–42 h after challenge. There
was no obvious difference in the spleen size in any of the experimental or
control groups of mice when the animals were killed. In some experiments
we determined SYVPSAEQI-CS-specific CD8  T cells using tetramers.
FACS analyses were done using FACSCalibur and CellQUEST software.
To determine whether sterile immunity had been elicited, the immu-
nized animals were challenged i.v. with 75 sporozoites. Peripheral blood
smears were made daily and were examined for the presence of blood
stages, starting from the third day after challenge, for a total of 2 wk. In the
P. yoelii model, blood infections result from the injection of 10 or less
sporozoites, and the prepatent period never exceeded 2 wk.
Detection of antibodies to CS. Anti-CS antibodies were detected by
an indirect immunofluorescence assay, using live or air-dried P. yoelii sporo-
zoites as described previously (37).
In vivo depletion of CD8  or CD4  T cells. Each vaccinated mouse re-
ceived daily 0.1 mg anti-CD4 mAb (from cell line  GK1.5) or anti-CD8 mAb
(from cell line  YTS 169; Harlan Bioproducts For Science) by i.p injection,
for three consecutive days. The mice were challenged with P. yoelii sporozoites
2 d after receiving the last dose of mAb. The corresponding protection and CS-
specific T cells were evaluated by real-time PCR and ELISPOT.
This work was supported by grants from the Starr Foundation and the Greenberg 
Medical Research Institute.
The authors have no conflicting financial interests.
Submitted: 2 August 2004
Accepted: 3 December 2004
REFERENCES
1. Lefeuvre, A., P. Marianneau, and V. Deubel. 2004. Current assessment of
yellow fever and yellow fever vaccine. Curr. Infect. Dis. Rep. 6:96–104.
2. Co, M.D., M. Terajima, J. Cruz, F.A. Ennis, and A.L. Rothman.
2002. Human cytotoxic T lymphocyte responses to live attenuated
17D yellow fever vaccine: identification of HLA-B35-restricted CTL
epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural
protein E. Virology. 293:151–163.
3. van der Most, R.G., L.E. Harrington, V. Giuggio, P.L. Mahar, and R.
Ahmed. 2002. Yellow fever virus 17D envelope and NS3 proteins are ma-
jor targets of the antiviral T cell response in mice. Virology. 296:117–124.
4. Monath, T.P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C.
Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, et al. 2003.
Chimeric live, attenuated vaccine against Japanese encephalitis (Chi-
meriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect
of vaccine dose and schedule, and memory response to challenge with
inactivated Japanese encephalitis antigen. J. Infect. Dis. 188:1213–1230.
5. Guirakhoo, F., K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K.
Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, et al. 2004. Safety
and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine
formulations in nonhuman primates. J. Virol. 78:4761–4775.
6. Marchevsky, R.S., M.S. Freire, E.S. Coutinho, and R. Galler. 2003.
Neurovirulence of yellow fever 17DD vaccine virus to rhesus mon-
keys. Virology. 316:55–63.
7. Bonaldo, M.C., R.C. Garratt, P.S. Caufour, M.S. Freire, M.M. Rod-
rigues, R.S. Nussenzweig, and R. Galler. 2002. Surface expression of
an immunodominant malaria protein B cell epitope by yellow fever vi-
rus. J. Mol. Biol. 315:873–885.
8. Romero, P., J.L. Maryanski, G. Corradin, R.S. Nussenzweig, V. Nus-
senzweig, and F. Zavala. 1989. Cloned cytotoxic T cells recognize an
epitope in the circumsporozoite protein and protect against malaria.
Nature. 341:323–326.
9. Herrington, D.A., D.F. Clyde, G. Losonsky, M. Cortesia, J.R. Murphy,
J. Davis, S. Baqar, A.M. Felix, E.P. Heimer, D. Gillessen, et al. 1987.
Safety and immunogenicity in man of a synthetic peptide malaria vaccine
against Plasmodium falciparum sporozoites. Nature. 328:257–259.
10. Stoute, J.A., M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, P.
Desmons, B.T. Wellde, N. Garcon, U. Krzych, and M. Marchand.
1997. A preliminary evaluation of a recombinant circumsporozoite
protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria
Vaccine Evaluation Group. N. Engl. J. Med. 336:86–91.
11. McAllister, A., A.E. Arbetman, S. Mandl, C. Pena-Rossi, and R. An-
dino. 2000. Recombinant yellow fever viruses are effective therapeutic
vaccines for treatment of murine experimental solid tumors and pul-
monary metastases. J. Virol. 74:9197–9205.
12. Gonzalez-Aseguinolaza, G., Y. Nakaya, A. Molano, E. Dy, M. Este-
ban, D. Rodriguez, J.R. Rodriguez, P. Palese, A. Garcia-Sastre, and
R.S. Nussenzweig. 2003. Induction of protective immunity against
malaria by priming-boosting immunization with recombinant cold-
adapted influenza and modified vaccinia Ankara viruses expressing a
CD8 -T-cell epitope derived from the circumsporozoite protein of
Plasmodium yoelii. J. Virol. 77:11859–11866.
13. Li, S., M. Rodrigues, D. Rodriguez, J.R. Rodriguez, M. Esteban, P.
Palese, R.S. Nussenzweig, and F. Zavala. 1993. Priming with recom-
binant influenza virus followed by administration of recombinant
vaccinia virus induces CD8  T-cell-mediated protective immunity
against malaria. Proc. Natl. Acad. Sci. USA. 90:5214–5218.
14. Tsuji, M., C.C. Bergmann, Y. Takita-Sonoda, K. Murata, E.G. Rod-
rigues, R.S. Nussenzweig, and F. Zavala. 1998. Recombinant Sindbis
viruses expressing a cytotoxic T-lymphocyte epitope of a malaria para-
site or of influenza virus elicit protection against the corresponding
pathogen in mice. J. Virol. 72:6907–6910.
15. Rodrigues, M., S. Li, K. Murata, D. Rodriguez, J.R. Rodriguez, I. Ba-
cik, J.R. Bennink, J.W. Yewdell, A. Garcia-Sastre, R.S. Nussenzweig, et
al. 1994. Influenza and vaccinia viruses expressing malaria CD8  T and
B cell epitopes. Comparison of their immunogenicity and capacity to in-
duce protective immunity. J. Immunol. 153:4636–4648.
16. Lindenbach, B.D., and C.M. Rice. 2001. Flaviviridae: The viruses and
their replication. In Fields Virology. D.M. Knipe and P.M. Howley,
editors. Lippincott Williams & Wilkins, Philadelphia. 991–1042.
17. Ploegh, H.L. 2004. Immunology. Nothing ‘gainst time’s scythe can
make defense. Science. 304:1262–1263.
18. Tassaneetrithep, B., T.H. Burgess, A. Granelli-Piperno, C. Trumpf-
heller, J. Finke, W. Sun, M.A. Eller, K. Pattanapanyasat, S. Sarasom-
bath, D.L. Birx, et al. 2003. DC-SIGN (CD209) mediates dengue vi-
rus infection of human dendritic cells. J. Exp. Med. 197:823–829.
19. Lalvani, A., P. Moris, G. Voss, A.A. Pathan, K.E. Kester, R. Brookes,JEM VOL. 201, January 17, 2005 209
ARTICLE
E. Lee, M. Koutsoukos, M. Plebanski, M. Delchambre, et al. 1999.
Potent induction of focused Th1-type cellular and humoral immune
responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum ma-
laria vaccine. J. Infect. Dis. 180:1656–1664.
20. Bojang, K.A., P.J. Milligan, M. Pinder, L. Vigneron, A. Alloueche,
K.E. Kester, W.R. Ballou, D.J. Conway, W.H. Reece, P. Gothard, et
al. 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium
falciparum infection in semi-immune adult men in The Gambia: a ran-
domised trial. Lancet. 358:1927–1934.
21. Reece, W.H., M. Pinder, P.K. Gothard, P. Milligan, K. Bojang, T.
Doherty, M. Plebanski, P. Akinwunmi, S. Everaere, K.R. Watkins, et
al. 2004. A CD4( ) T-cell immune response to a conserved epitope in
the circumsporozoite protein correlates with protection from natural
Plasmodium falciparum infection and disease. Nat. Med. 10:406–410.
22. Saul, A., V. Nussenzweig, and R.S. Nussenzweig. 2004. Rationale for
malaria vaccine development. In Novel Vaccination Strategies. S.H.E.
Kaufmann, editor. Wiley-VCH, Weinheim. 479–503.
23. Wang, Q., S. Brown, D.S. Roos, V. Nussenzweig, and P. Bhanot.
2004. Transcriptome of axenic liver stages of Plasmodium yoelii. Mol.
Biochem. Parasitol. 137:161–168.
24. Hamilton, A.J., A. Suhrbier, J. Nicholas, and R.E. Sinden. 1988. Im-
munoelectron microscopic localization of circumsporozoite antigen in
the differentiating exoerythrocytic trophozoite of Plasmodium berghei.
Cell Biol. Int. Rep. 12:123–129.
25. Moorthy, V.S., E.B. Imoukhuede, S. Keating, M. Pinder, D. Webster,
M.A. Skinner, S.C. Gilbert, G. Walraven, and A.V. Hill. 2004. Phase 1
evaluation of 3 highly immunogenic prime-boost regimens, including
a 12-month reboosting vaccination, for malaria vaccination in Gam-
bian men. J. Infect. Dis. 189:2213–2219.
26. Robertson, S. 1993. Module 8: Yellow fever. In The Immunological
Basis for Immunization. WHO, Global Programme for Vaccines and
Immunization, Geneva.
27. Chan, R.C., D.J. Penney, D. Little, I.W. Carter, J.A. Roberts, and
W.D. Rawlinson. 2001. Hepatitis and death following vaccination
with 17D-204 yellow fever vaccine. Lancet. 358:121–122.
28. Galler, R., K.V. Pugachev, C.L. Santos, S.W. Ocran, A.V. Jabor, S.G.
Rodrigues, R.S. Marchevsky, M.S. Freire, L.F. Almeida, A.C. Cruz, et
al. 2001. Phenotypic and molecular analyses of yellow fever 17DD
vaccine viruses associated with serious adverse events in Brazil. Virol-
ogy. 290:309–319.
29. Martin, M., T.F. Tsai, B. Cropp, G.J. Chang, D.A. Holmes, J. Tseng,
W. Shieh, S.R. Zaki, I. Al-Sanouri, A.F. Cutrona, et al. 2001. Fever
and multisystem organ failure associated with 17D-204 yellow fever
vaccination: a report of four cases. Lancet. 358:98–104.
30. WHO. 2003. Yellow fever vaccine: WHO position paper. Wkly. Epi-
demiol. Rec. 78:349–360.
31. Khromykh, A.A., A.N. Varnavski, P.L. Sedlak, and E.G. Westaway.
2001. Coupling between replication and packaging of flavivirus RNA:
evidence derived from the use of DNA-based full-length cDNA clones
of Kunjin virus. J. Virol. 75:4633–4640.
32. Bredenbeek, P.J., E.A. Kooi, B. Lindenbach, N. Huijkman, C.M.
Rice, and W.J. Spaan. 2003. A stable full-length yellow fever virus
cDNA clone and the role of conserved RNA elements in flavivirus
replication. J. Gen. Virol. 84:1261–1268.
33. Amberg, S.M., and C.M. Rice. 1999. Mutagenesis of the NS2B-NS3-
mediated cleavage site in the flavivirus capsid protein demonstrates a
requirement for coordinated processing. J. Virol. 73:8083–8094.
34. Rice, C.M., L. Dalgarno, R. Galler, Y.S. Hahn, E.G. Strauss, and J.H.
Strauss. 1988. Molecular cloning of flavivirus genomes for comparative
analysis and expression. In Modern Trends in Virology. C. Scholtissek,
editor. Springer-Verlag, Berlin. 83–97.
35. Bruna-Romero, O., J.C. Hafalla, G. Gonzalez-Aseguinolaza, G. Sano,
M. Tsuji, and F. Zavala. 2001. Detection of malaria liver-stages in mice
infected through the bite of a single Anopheles mosquito using a highly
sensitive real-time PCR. Int. J. Parasitol. 31:1499–1502.
36. Carvalho, L.H., J.C. Hafalla, and F. Zavala. 2001. ELISPOT assay to
measure antigen-specific murine CD8( ) T cell responses. J. Immunol.
Methods. 252:207–218.
37. Nardin, E., R.W. Gwadz, and R.S. Nussenzweig. 1979. Characteriza-
tion of sporozoite surface antigens by indirect immunofluorescence:
detection of stage- and species-specific antimalarial antibodies. Bull.
World Health Organ. 57:211–217.